SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9478	Companies
185492	Keywords
117871	Articles
99349	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 06/02/2025 at 07:05, 6 months 3 days ago

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Rare Diseases Sanofi Acquisition Blueprint Medicines Immunology Pipeline Systemic Mastocytosis
PRESS RELEASE

published on 06/02/2025 at 07:00, 6 months 3 days ago

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease. Acquisition includes Ayvakit/Ayvakyt for systemic mastocytosis and a promising pipeline in immunology

Acquisition Sanofi Rare Diseases Blueprint Medicines Immunological Disease
BRIEF

published on 05/30/2025 at 07:05, 6 months 6 days ago

Itepekimab Reaches Primary Endpoint in COPD Phase 3 Study

Sanofi COPD Regeneron Itepekimab AERIFY-1
PRESS RELEASE

published on 05/30/2025 at 07:00, 6 months 6 days ago

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met primary endpoint in AERIFY-1 study for COPD, with significant reduction in exacerbations. AERIFY-2 did not meet endpoint. Sanofi and Regeneron assessing data for next steps

Sanofi COPD Regeneron Itepekimab AERIFY-1
BRIEF

published on 05/29/2025 at 14:35, 6 months 7 days ago

Positive impact of Beyfortus on hospitalizations due to RSV

Public Health Efficiency Beyfortus VRS Hospitalizations Childhood Vaccination
PRESS RELEASE

published on 05/29/2025 at 14:30, 6 months 7 days ago

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Real-world comparison shows Beyfortus and RSVpreF immunization programs reduce infant RSV hospitalizations in Spain and UK. Beyfortus provides sustained protection against RSV with high efficacy and safety profile

RSV Beyfortus RSVpreF Infant Immunization
BRIEF

published on 05/22/2025 at 01:20, 6 months 14 days ago

Sanofi acquires Vigil Neuroscience to strengthen its Alzheimer's research

Acquisition Alzheimer's Disease Sanofi Neurology Vigil Neuroscience
PRESS RELEASE

published on 05/22/2025 at 01:15, 6 months 14 days ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist

Alzheimer's Disease Sanofi Neurology Vigil Neuroscience VG-3927
BRIEF

published on 05/15/2025 at 19:11, 6 months 20 days ago

Sanofi: Details on Voting Rights and Shares - April 2025

Voting Rights Actions Investment Sanofi April 2025
BRIEF

published on 04/30/2025 at 13:05, 7 months 5 days ago

Sanofi and CD&R finalize the sale of Opella

Sanofi CD&R Assignment Opella Consumer Health

Accesswire

Published on 12/05/2025 at 16:00, 33 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 48 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 58 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 8 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 1 hour 33 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 16:25, 8 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 23 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 33 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 33 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 33 minutes ago

Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

Les Echos

Published on 12/05/2025 at 15:10, 1 hour 22 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 48 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 22 hours 33 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 48 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 49 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE